<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Korean J Ophthalmol</journal-id><journal-id journal-id-type="publisher-id">KJO</journal-id><journal-title-group><journal-title>Korean Journal of Ophthalmology : KJO</journal-title></journal-title-group><issn pub-type="ppub">1011-8942</issn><publisher><publisher-name>The Korean Ophthalmological Society</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">17302204</article-id><article-id pub-id-type="pmc">2908852</article-id><article-id pub-id-type="doi">10.3341/kjo.2006.20.4.205</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Intravitreal versus Posterior Subtenon Injection of Triamcinolone Acetonide for Diabetic Macular Edema</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Choi</surname><given-names>Young Jae</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A1"></xref></contrib><contrib contrib-type="author"><name><surname>Oh</surname><given-names>In Kyung</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A1"></xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Oh</surname><given-names>Jae Ryung</given-names></name><degrees>MD</degrees><degrees>PhD</degrees><xref ref-type="aff" rid="A1"></xref></contrib><contrib contrib-type="author"><name><surname>Huh</surname><given-names>Kuhl</given-names></name><degrees>MD</degrees><degrees>PhD</degrees><xref ref-type="aff" rid="A1"></xref></contrib></contrib-group><aff id="A1">Department of Ophthalmology, Korea University College of Medicine, Seoul, Korea.</aff><author-notes><corresp>
Reprint requests to Jaeryung Oh, MD, PhD. Department of Ophthalmology, Korea University College of Medicine, #126-1 Anam-dong 5-ga, Sungbuk-gu, Seoul 136-705, Korea. Tel: 82-2-920-5521, Fax: 82-2-924-6820, <email>ojr4991@yahoo.co.kr</email></corresp></author-notes><pub-date pub-type="ppub"><month>12</month><year>2006</year></pub-date><pub-date pub-type="epub"><day>31</day><month>12</month><year>2006</year></pub-date><volume>20</volume><issue>4</issue><fpage>205</fpage><lpage>209</lpage><history><date date-type="received"><day>31</day><month>3</month><year>2006</year></date><date date-type="accepted"><day>15</day><month>11</month><year>2006</year></date></history><permissions><copyright-statement>Copyright © 2006 by the Korean Ophthalmological Society</copyright-statement><copyright-year>2006</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title><offsets xml_i="3281" xml_f="3288" txt_i="11" txt_f="18">Purpose</offsets></title><p><offsets xml_i="3299" xml_f="3439" txt_i="19" txt_f="159">To compare the short-term effects of intravitreal versus posterior subtenon injection of triamcinolone acetonide for diabetic macular edema.</offsets></p></sec><sec><title><offsets xml_i="3461" xml_f="3468" txt_i="161" txt_f="168">Methods</offsets></title><p><offsets xml_i="3479" xml_f="3930" txt_i="169" txt_f="620">This is a prospective and interventional study. Sixty eyes of 60 patients who had diffuse diabetic macular edema were assigned to receive a single intravitreal injection (4 mg) or a single posterior subtenon injection (40 mg) of triamcinolone acetonide. The central retinal thickness was measured using optical coherent tomography before injection and at 1 and 3 months after injection. Visual acuity and intraocular pressure (IOP) were also measured.</offsets></p></sec><sec><title><offsets xml_i="3952" xml_f="3959" txt_i="622" txt_f="629">Results</offsets></title><p><offsets xml_i="3970" xml_f="4406" txt_i="630" txt_f="1066">Both intravitreal and posterior subtenon injections of triamcinolone acetonide resulted in significant improvements in visual acuity at 1 month and 3 months after injection. Both groups resulted in a significant decrease in central macular thickness (CMT) at 1 month and 3 months post-injection. IOP in the intravitreal injection group was significantly higher than in the posterior subtenon injection group at 3 months after injection.</offsets></p></sec><sec><title><offsets xml_i="4428" xml_f="4439" txt_i="1068" txt_f="1079">Conclusions</offsets></title><p><offsets xml_i="4450" xml_f="4753" txt_i="1080" txt_f="1383">The posterior subtenon injection of triamcinolone acetonide had a comparable effect to the intravitreal triamcinolone injection and showed a lower risk of elevated IOP. Posterior subtenon injection of triamcinolone acetonide may be a good alternative for the treatment of diffuse diabetic macular edema.</offsets></p></sec></abstract><kwd-group><kwd>Diffuse diabetic macular edema</kwd><kwd>Intravitreal injection</kwd><kwd>Posterior subtenon injection</kwd><kwd>Triamcinolone acetonide</kwd></kwd-group></article-meta></front><body><p><offsets xml_i="4976" xml_f="5491" txt_i="1392" txt_f="1907">Diabetic macular edema is a common cause of visual loss in patients with diabetic retinopathy. It may occur by focal leakage from microaneurysms, which is often associated with intraretinal lipid deposition in a circinate pattern, and by diffuse leakage from the perifoveal retinal capillaries. In the Early Treatment Diabetic Retinopathy Study (ETDRS), focal laser photocoagulation was applied for leakages from the microaneurysms and grid laser photocoagulation was applied for areas of diffuse capillary leakage.</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="5522" xml_f="5523" txt_i="1907" txt_f="1908">1</offsets></xref><offsets xml_i="5530" xml_f="5531" txt_i="1908" txt_f="1909">,</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="5562" xml_f="5563" txt_i="1909" txt_f="1910">2</offsets></xref><offsets xml_i="5570" xml_f="5711" txt_i="1910" txt_f="2051"> However, several studies have shown that eyes with diffuse macular edema carry a particularly poor prognosis despite laser photocoagulation.</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="5742" xml_f="5743" txt_i="2051" txt_f="2052">3</offsets></xref><offsets xml_i="5750" xml_f="5751" txt_i="2052" txt_f="2053">,</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="5782" xml_f="5783" txt_i="2053" txt_f="2054">4</offsets></xref><offsets xml_i="5790" xml_f="5804" txt_i="2054" txt_f="2068"> In the ETDRS,</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="5835" xml_f="5836" txt_i="2068" txt_f="2069">1</offsets></xref><offsets xml_i="5843" xml_f="5969" txt_i="2069" txt_f="2195"> only 17% of the eyes had any improvement in visual acuity and less than 3% had a visual improvement of 3 or more ETDRS lines.</offsets></p><p><offsets xml_i="5976" xml_f="6126" txt_i="2196" txt_f="2346">In recent years, the intravitreal administration of triamcinolone acetonide has provided promising results for the treatment of diffuse macular edema.</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="6157" xml_f="6158" txt_i="2346" txt_f="2347">5</offsets></xref><offsets xml_i="6165" xml_f="6166" txt_i="2347" txt_f="2348">-</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="6197" xml_f="6198" txt_i="2348" txt_f="2349">9</offsets></xref><offsets xml_i="6205" xml_f="6293" txt_i="2349" txt_f="2437"> However, the risk of ocular complications such as intraocular pressure (IOP) elevation,</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="6325" xml_f="6327" txt_i="2437" txt_f="2439">10</offsets></xref><offsets xml_i="6334" xml_f="6335" txt_i="2439" txt_f="2440">-</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="6367" xml_f="6369" txt_i="2440" txt_f="2442">12</offsets></xref><offsets xml_i="6376" xml_f="6393" txt_i="2442" txt_f="2459"> endophthalmitis,</offsets><xref ref-type="bibr" rid="B13"><offsets xml_i="6425" xml_f="6427" txt_i="2459" txt_f="2461">13</offsets></xref><offsets xml_i="6434" xml_f="6480" txt_i="2461" txt_f="2507"> retinal detachment and glaucoma was reported.</offsets></p><p><offsets xml_i="6487" xml_f="6802" txt_i="2508" txt_f="2823">Posterior subtenon injection of a steroid is an alternative method with proven effectiveness in various ocular diseases like cystoid macular edema and intermediate uveitis. Posterior subtenon injection of triamcinolone has also been reported to be an effective and safe treatment for diffuse diabetic macular edema.</offsets><xref ref-type="bibr" rid="B14"><offsets xml_i="6834" xml_f="6836" txt_i="2823" txt_f="2825">14</offsets></xref></p><p><offsets xml_i="6850" xml_f="7043" txt_i="2826" txt_f="3019">We performed a prospective study to compare effectiveness and safety between intravitreal and posterior subtenon injection of triamcinolone acetonide for the treatment of diffuse macular edema.</offsets></p><sec sec-type="materials|methods"><title><offsets xml_i="7088" xml_f="7109" txt_i="3020" txt_f="3041">Materials and Methods</offsets></title><p><offsets xml_i="7120" xml_f="7876" txt_i="3042" txt_f="3795">Sixty eyes of 60 patients with macular edema involving the fovea were enrolled in this study. Diffuse macular edema was defined by central thickening on a biomicroscopy using a 90-diopter noncontact lens and by diffuse fluorescein leakage on fluorescein angiography. Central macular thickness (CMT) was required to be &gt;250 µm on an optical coherent tomography (OCT). Patients with other pathologies of macula or optic disc such as glaucoma or ocular hypertension were excluded. Patients with extensive foveal ischemia with more than one disc diameter of capillary closure on fluorescein angiography were excluded. Patients who had undergone intraocular surgery or macular grid laser photocoagulation within 3 months prior to the injection were excluded.</offsets></p><p><offsets xml_i="7883" xml_f="8156" txt_i="3796" txt_f="4069">One of the authors (K.H.) performed intravitreal injection and another (J.O.) performed posterior subtenon injection during the same period. The physicians who checked visual acuity, IOP and CMT had not been informed of the purpose of this study or the assignment schedule.</offsets></p><p><offsets xml_i="8163" xml_f="9240" txt_i="4070" txt_f="5147">Intravitreal injection was done under sterile conditions in the operating room. Eyes receiving the intravitreal injection were anesthetized by topical instillation of 0.5% proparacaine hydrochloride. Under the operating microscope, 0.1 ml of triamcinolone acetonide (4 mg) was injected slowly via a 30-gauge needle through the pars plana, 3.0 mm posterior to the limbus in the pseudopakic eyes and 4.0 mm posterior to the limbus in phakic eyes. For the posterior subtenon injection, under topical anesthesia (0.5% proparacaine hydrochloride), a small incision (8 mm posterior to the limbus) was made through the superotemporal forniceal conjunctiva and tenon's capsule to bare the sclera using Westcott scissors. The curved portion of the pinpoint cannula was inserted and a volume of 1 ml containing 40 mg triamcinolone was slowly injected behind the eye through the incision site. After the triamcinolone application was completed, the cannula was withdrawn slowly, with gentle pressure maintained by a sterile swab along the path of the cannula. No drug reflux was observed.</offsets></p><p><offsets xml_i="9247" xml_f="9946" txt_i="5148" txt_f="5847">The patients were evaluated on the basis of central retinal thickness from OCT, visual acuity and IOP. All the patients underwent these examinations before injection and at 1 week, 1 month and 3 months post-injection. During the OCT procedure, each eye underwent six radial scans centered on the fovea. The value which printed on the OCT automated mode determined the central retinal thickness. The best-corrected visual acuity on the decimal charts was examined at each visit and was converted to the logarithm of minimal angle of resolution (logMAR) scale for statistical analysis. The IOP was measured using Goldmann applanation tonometry and the number of glaucoma medications used was recorded.</offsets></p><p><offsets xml_i="9953" xml_f="10246" txt_i="5848" txt_f="6141">The temporal changes in logMAR visual acuity, central retinal thickness and IOP were compared using the Wilcoxon signed rank test. The differences between groups in logMAR visual acuity, central retinal thickness, IOP and other continuous variables were compared using the Mann-Whitney U test.</offsets></p></sec><sec sec-type="results"><title><offsets xml_i="10287" xml_f="10294" txt_i="6143" txt_f="6150">Results</offsets></title><p><offsets xml_i="10305" xml_f="10504" txt_i="6151" txt_f="6350">The mean age of the patients (±SD) was 60.69±10.8 years, with a range of 46 to 70 years. The mean (±SD) duration of diabetes was 16.3±8.1 years (range, 4-30 years). Patient demographics are shown in </offsets><xref ref-type="table" rid="T1"><offsets xml_i="10536" xml_f="10543" txt_i="6350" txt_f="6357">Table 1</offsets></xref><offsets xml_i="10550" xml_f="10715" txt_i="6357" txt_f="6522">. No statistically significant differences were found between groups regarding age, gender, the ratio of left to right eyes, the ratio of PDR to NPDR or DM duration.</offsets></p><p><offsets xml_i="10722" xml_f="10851" txt_i="6523" txt_f="6652">The mean (±SD) visual acuity before triamcinolone acetonide injection and at 1 week, 1 month and 3 months thereafter is shown in </offsets><xref ref-type="table" rid="T2"><offsets xml_i="10883" xml_f="10890" txt_i="6652" txt_f="6659">Table 2</offsets></xref><offsets xml_i="10897" xml_f="10902" txt_i="6659" txt_f="6664"> and </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="10932" xml_f="10938" txt_i="6664" txt_f="6670">Fig. 1</offsets></xref><offsets xml_i="10945" xml_f="11698" txt_i="6670" txt_f="7423">. The mean baseline visual acuity was not significantly different between the 2 groups (p=0.338). In both groups, the visual acuity significantly improved throughout the study. In the intravitreal injection group, the mean visual acuity at 1 month (0.571±0.393; p=0.001) and 3 months (0.535±0.382; p=0.001) after the injection were significantly better than baseline measurements. In the posterior subtenon injection group, the mean visual acuity at 1 month (0.650±0.281; p=0.011) and 3 months (0.623±0.264; p=0.007) after the injection was also significantly better than the baseline measurements. Between the 2 groups, there were no significant differences in the mean visual acuity changes before injection or at 1 month and 3 months after injection.</offsets></p><p><offsets xml_i="11705" xml_f="11911" txt_i="7424" txt_f="7630">The mean baseline CMT was not significantly different between the 2 groups (p=0.461). In both the intravitreal and posterior subtenon injection group, the CMT was significantly decreased through the study (</offsets><xref ref-type="table" rid="T3"><offsets xml_i="11943" xml_f="11950" txt_i="7630" txt_f="7637">Table 3</offsets></xref><offsets xml_i="11957" xml_f="11959" txt_i="7637" txt_f="7639">, </offsets><xref ref-type="fig" rid="F2"><offsets xml_i="11989" xml_f="11995" txt_i="7639" txt_f="7645">Fig. 2</offsets></xref><offsets xml_i="12002" xml_f="12273" txt_i="7645" txt_f="7916">). At 3 months after injection, OCT demonstrated a reduction of the mean CMT (intravitreal group: 46.2%, subtenon group: 43.5%). Between the 2 groups, there was no significant difference in the mean CMT change before injection or at 1 month and 3 months after injection. </offsets><xref ref-type="fig" rid="F3"><offsets xml_i="12303" xml_f="12309" txt_i="7916" txt_f="7922">Fig. 3</offsets></xref><offsets xml_i="12316" xml_f="12482" txt_i="7922" txt_f="8088"> illustrates the changes in the OCT images of a representative patient in the intravitreal injection group and of a patient in the posterior subtenon injection group.</offsets></p><p><offsets xml_i="12489" xml_f="12699" txt_i="8089" txt_f="8299">The mean baseline IOP did not show differences between the 2 groups (p=0.524). In the intravitreal injection group, IOP tended to rise after the injection although the change was not statistically significant (</offsets><xref ref-type="table" rid="T4"><offsets xml_i="12731" xml_f="12738" txt_i="8299" txt_f="8306">Table 4</offsets></xref><offsets xml_i="12745" xml_f="12747" txt_i="8306" txt_f="8308">, </offsets><xref ref-type="fig" rid="F4"><offsets xml_i="12777" xml_f="12783" txt_i="8308" txt_f="8314">Fig. 4</offsets></xref><offsets xml_i="12790" xml_f="13215" txt_i="8314" txt_f="8739">). Ten eyes (33%) experienced an IOP elevation to 21 mmHg or higher during the follow-up period. In the posterior subtenon injection group, a temporal change of IOP was not found. Only 1 eye (3.3%) experienced an IOP of 21 mmHg or higher during the follow up period. At 3 months after injection, the IOP change of the intravitreal injected eyes was greater than that of the posterior subtenon capsule injected eyes (p=0.026).</offsets></p></sec><sec sec-type="discussion"><title><offsets xml_i="13259" xml_f="13269" txt_i="8741" txt_f="8751">Discussion</offsets></title><p><offsets xml_i="13280" xml_f="13546" txt_i="8752" txt_f="9018">This study demonstrates that intravitreal injection or posterior subtenon injection has a beneficial effect in reducing the diabetic macular edema. Two groups did not show any significant difference in visual acuity or mean CMT thickness improvement after injection.</offsets></p><p><offsets xml_i="13553" xml_f="13900" txt_i="9019" txt_f="9366">In this study, the change of mean visual acuity (LogMAR) after intravitreal injection was 0.160 (21.8%) at 1 month and 0.196 (26.8%) at 3 months after the injection. The change of mean CMT was 171.6 µm (40.1%) at 1 month and 197.7 µm (46.2%) at 3 months after intravitreal injection. These results were similar to previous studies. Martidis et al.</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="13931" xml_f="13932" txt_i="9366" txt_f="9367">5</offsets></xref><offsets xml_i="13939" xml_f="14076" txt_i="9367" txt_f="9504"> reported that CMT decreased by 55% and 57.5% at 1 and 3 months after intravitreal trimcinolone injection, respectively. Ciardella et al.</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="14107" xml_f="14108" txt_i="9504" txt_f="9505">8</offsets></xref><offsets xml_i="14115" xml_f="14165" txt_i="9505" txt_f="9555"> reported decreases of 42% and 46.4%. Jonas et al.</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="14196" xml_f="14197" txt_i="9555" txt_f="9556">9</offsets></xref><offsets xml_i="14204" xml_f="14357" txt_i="9556" txt_f="9709"> reported that visual acuity(LogMAR) improved by 0.15 (15.3%) and 0.19 (19.3%) at 1 and 3 months after intravitreal trimcinolone injection, respectively.</offsets></p><p><offsets xml_i="14364" xml_f="14590" txt_i="9710" txt_f="9936">Posterior subtenon injection of triamcinolone has been used with proven effectiveness in conditions with a breakdown in the blood-retinal barrier, such as cystoid macular edema and intermediate uveitis. Recently, Ohguro et al.</offsets><xref ref-type="bibr" rid="B14"><offsets xml_i="14622" xml_f="14624" txt_i="9936" txt_f="9938">14</offsets></xref><offsets xml_i="14631" xml_f="14836" txt_i="9938" txt_f="10143"> reported an observational case series indicating the effectiveness of posterior subtenon triamcinolone infusion in diffuse diabetic macular edema in eyes that had not responded to vitrectomy. Bakri et al.</offsets><xref ref-type="bibr" rid="B15"><offsets xml_i="14868" xml_f="14870" txt_i="10143" txt_f="10145">15</offsets></xref><offsets xml_i="14877" xml_f="15115" txt_i="10145" txt_f="10383"> also reported that visual acuities remained stable or improved over a 12-month period after posterior subtenon triamcinolone injections for refractory diabetic macular edema. These recent results have a general connection with our study.</offsets></p><p><offsets xml_i="15122" xml_f="15136" txt_i="10384" txt_f="10398">Freeman et al.</offsets><xref ref-type="bibr" rid="B16"><offsets xml_i="15168" xml_f="15170" txt_i="10398" txt_f="10400">16</offsets></xref><offsets xml_i="15177" xml_f="15332" txt_i="10400" txt_f="10555"> have shown by ultrasound B-scan that the superotemporal placement technique results in more accurate placement of steroids near the macula. Geroski et al.</offsets><xref ref-type="bibr" rid="B17"><offsets xml_i="15364" xml_f="15366" txt_i="10555" txt_f="10557">17</offsets></xref><offsets xml_i="15373" xml_f="15479" txt_i="10557" txt_f="10663"> reported the usefulness of the transscleral pathway in delivering the drug to the retina. Weijtens et al.</offsets><xref ref-type="bibr" rid="B18"><offsets xml_i="15511" xml_f="15513" txt_i="10663" txt_f="10665">18</offsets></xref><offsets xml_i="15520" xml_f="15856" txt_i="10665" txt_f="11001"> reported that the intravitreal concentration of the steroid increased after its peribulbar injection. On the basis of these reports, it can be summarized that the injected triamcinolone is located on the subtenon macular area and its therapeutic concentration on the choroids or retina can be obtained through the transscleral pathway.</offsets></p><p><offsets xml_i="15863" xml_f="15878" txt_i="11002" txt_f="11017">Cardillo et al.</offsets><xref ref-type="bibr" rid="B19"><offsets xml_i="15910" xml_f="15912" txt_i="11017" txt_f="11019">19</offsets></xref><offsets xml_i="15919" xml_f="16209" txt_i="11019" txt_f="11309"> compared intravitreal injection with posterior subtenon injection of triamcinolone in diabetic macular edema. They concluded that the intravitreal injection was more favorable than the posterior subtenon injection for the anatomic and functional aspects of improvement. Bonini-Filho et al.</offsets><xref ref-type="bibr" rid="B20"><offsets xml_i="16241" xml_f="16243" txt_i="11309" txt_f="11311">20</offsets></xref><offsets xml_i="16250" xml_f="16989" txt_i="11311" txt_f="12050"> also suggested that intravitreal injection may be more effective than posterior subtenon injection for the management of refractive diffuse diabetic macular edema. These two studies differ from our results in that our study show that both intravitreal and posterior subtenon injections may be equally tolerated with a short-term performance. The study of Cardillo et al was informative in that two approaches were performed to each eye of the same patient with bilateral symmetric diffuse macular edema. However one limitation of the study was the relatively small sample size (12 patients). In Bonini-Filho et al's study, the patients had refractive diabetic macular edema. Thus, their results cannot directly be compared to our results.</offsets></p><p><offsets xml_i="16996" xml_f="17170" txt_i="12051" txt_f="12225">One advantages of posterior subtenon administration is a lower risk of complication. IOP elevation is the most common complication after intravitreal triamcinolone injection.</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="17202" xml_f="17204" txt_i="12225" txt_f="12227">10</offsets></xref><offsets xml_i="17211" xml_f="17212" txt_i="12227" txt_f="12228">-</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="17244" xml_f="17246" txt_i="12228" txt_f="12230">12</offsets></xref><offsets xml_i="17253" xml_f="17640" txt_i="12230" txt_f="12617"> Although not statistically significant, IOP after intravitreal injection tended to rise in our study. At 3 months after injection, the change of IOP in the intravitreal injection group was greater than that of the posterior subtenon injection group. Other complications such as endophthalmitis and retinal detachment were also reported following intravitreal injection in other studies.</offsets></p><p><offsets xml_i="17647" xml_f="18054" txt_i="12618" txt_f="13025">In conclusion, the short-term efficacy of the intravitreal injection and of the posterior subtenon injection of triamcinolone in diffuse diabetic macular edema was similar. The posterior subtenon injection was less invasive and safer than the intravitreal injection. Therefore, posterior subtenon injection of triamcinolone acetonide may be a good option for the treatment of diffuse diabetic macular edema.</offsets></p></sec></body><back><fn-group><fn fn-type="presented-at"><p>This study was presented in part at the 94th Annual meeting of the Korean Ophthalmological Society, October 2005.</p></fn></fn-group><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><collab>Early Treatment Diabetic Retinopathy Study Research Group</collab><article-title>Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1</article-title><source>Arch Ophthalmol</source><year>1985</year><volume>103</volume><fpage>1796</fpage><lpage>1806</lpage><pub-id pub-id-type="pmid">2866759</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><collab>Early Treatment Diabetic Retinopathy Study Research Group</collab><article-title>Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 2</article-title><source>Ophthalmology</source><year>1987</year><volume>94</volume><fpage>761</fpage><lpage>774</lpage><pub-id pub-id-type="pmid">3658348</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>CM</given-names></name><name><surname>Olk</surname><given-names>RJ</given-names></name></person-group><article-title>Modified grid laser photocoagulation for diffuse macular oedema: long-term visual results</article-title><source>Ophthalmology</source><year>1991</year><volume>98</volume><fpage>1594</fpage><lpage>1602</lpage><pub-id pub-id-type="pmid">1961650</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><collab>Early Treatment Diabetic Retinopathy Study Research Group</collab><article-title>Focal photocoagulation treatment of diabetic macular edema. Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS report no.19</article-title><source>Arch Ophthalmol</source><year>1995</year><volume>113</volume><fpage>1144</fpage><lpage>1155</lpage><pub-id pub-id-type="pmid">7661748</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martidis</surname><given-names>A</given-names></name><name><surname>Duker</surname><given-names>JS</given-names></name><name><surname>Greenberg</surname><given-names>PB</given-names></name><etal></etal></person-group><article-title>Intravitreal Triamcinolone for Refractory Diabetic Macular Edema</article-title><source>Ophthalmology</source><year>2002</year><volume>109</volume><fpage>920</fpage><lpage>927</lpage><pub-id pub-id-type="pmid">11986098</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Massin</surname><given-names>P</given-names></name><name><surname>Audren</surname><given-names>F</given-names></name><name><surname>Haouchine</surname><given-names>B</given-names></name><etal></etal></person-group><article-title>Intravitreal Triamcinolone Acetonide for Diabetic Diffuse Macular Edema; Preliminary Results of a Prospective Controlled Trial</article-title><source>Ophthalmology</source><year>2004</year><volume>111</volume><fpage>218</fpage><lpage>225</lpage><pub-id pub-id-type="pmid">15019365</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karacorlu</surname><given-names>M</given-names></name><name><surname>Ozdemir</surname><given-names>H</given-names></name><name><surname>Karacorlu</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>Intravitreal triamcinolone as a primary therapy in diabetic macular oedema</article-title><source>Eye</source><year>2004</year><volume>19</volume><fpage>382</fpage><lpage>386</lpage><pub-id pub-id-type="pmid">15309024</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ciardella</surname><given-names>AP</given-names></name><name><surname>Klancnik</surname><given-names>J</given-names></name><name><surname>Schiff</surname><given-names>W</given-names></name><etal></etal></person-group><article-title>Intravitreal triamcinolone for the treatment of refractory diabetic macular oedema with hard exudates: an optical coherence tomography study</article-title><source>Br J Ophthalmol</source><year>2004</year><volume>88</volume><fpage>1131</fpage><lpage>1136</lpage><pub-id pub-id-type="pmid">15317702</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jonas</surname><given-names>JB</given-names></name><name><surname>Akkoyun</surname><given-names>I</given-names></name><name><surname>Kreissig</surname><given-names>I</given-names></name><etal></etal></person-group><article-title>Diffuse diabetic macular oedema treated by intravitreal triamcinolone acetonide: a comparative, non-randomised study</article-title><source>Br J Ophthalmol</source><year>2005</year><volume>89</volume><fpage>321</fpage><lpage>326</lpage><pub-id pub-id-type="pmid">15722313</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jonas</surname><given-names>JB</given-names></name><name><surname>Degenring</surname><given-names>RF</given-names></name><name><surname>Kreissig</surname><given-names>I</given-names></name><etal></etal></person-group><article-title>Intraocular Pressure Elevation after Intravitreal Triamcinolone Acetonide Injection</article-title><source>Ophthalmology</source><year>2005</year><volume>112</volume><fpage>593</fpage><lpage>598</lpage><pub-id pub-id-type="pmid">15808249</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smithen</surname><given-names>LM</given-names></name><name><surname>Ober</surname><given-names>MD</given-names></name><name><surname>Maranan</surname><given-names>L</given-names></name><etal></etal></person-group><article-title>Intravitreal Triamcinolone Acetonide and Intraocular Pressure</article-title><source>Am J Ophthalmol</source><year>2004</year><volume>138</volume><fpage>740</fpage><lpage>743</lpage><pub-id pub-id-type="pmid">15531307</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>HY</given-names></name><name><surname>Yi</surname><given-names>K</given-names></name><name><surname>Kim</surname><given-names>HK</given-names></name></person-group><article-title>Intraocular pressure elevation after intravitreal triamcinolone acetonide injection</article-title><source>Korean J Ophthalmol</source><year>2005</year><volume>19</volume><fpage>122</fpage><lpage>127</lpage><pub-id pub-id-type="pmid">15988928</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moshfeghi</surname><given-names>DM</given-names></name><name><surname>Kaiser</surname><given-names>PK</given-names></name><name><surname>Scott</surname><given-names>IU</given-names></name><etal></etal></person-group><article-title>Acute Endophthalmitis Following Intravitreal Triamcinolone Acetonide Injection</article-title><source>Am J Ophthalmol</source><year>2003</year><volume>136</volume><fpage>791</fpage><lpage>796</lpage><pub-id pub-id-type="pmid">14597028</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohguro</surname><given-names>N</given-names></name><name><surname>Okada</surname><given-names>AA</given-names></name><name><surname>Tano</surname><given-names>Y</given-names></name></person-group><article-title>Trans-Tenon's retrobulbar triamcinolone infusion for diffuse diabetic macular edema</article-title><source>Graefes Arch Clin Exp Ophthalmol</source><year>2004</year><volume>242</volume><fpage>444</fpage><lpage>445</lpage><pub-id pub-id-type="pmid">14747952</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bakri</surname><given-names>SJ</given-names></name><name><surname>Kaiser</surname><given-names>PK</given-names></name></person-group><article-title>Posterior Subtenon Triamcinolone Acetonide for Refractory Diabetic Macular Edema</article-title><source>Am J Ophthalmol</source><year>2005</year><volume>139</volume><fpage>290</fpage><lpage>294</lpage><pub-id pub-id-type="pmid">15733990</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freeman</surname><given-names>WR</given-names></name><name><surname>Green</surname><given-names>RL</given-names></name><name><surname>Smith</surname><given-names>RE</given-names></name></person-group><article-title>Echographic localization of corticosteroids after periocular injection</article-title><source>Am J Ophthalmol</source><year>1987</year><volume>130</volume><fpage>281</fpage><lpage>288</lpage><pub-id pub-id-type="pmid">3548390</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geroski</surname><given-names>DH</given-names></name><name><surname>Edelhauser</surname><given-names>HF</given-names></name></person-group><article-title>Transscleral drug delivery for posterior segment disease</article-title><source>Adv Drug Deliv Rev</source><year>2001</year><volume>52</volume><fpage>37</fpage><lpage>48</lpage><pub-id pub-id-type="pmid">11672874</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weijtens</surname><given-names>O</given-names></name><name><surname>van der Sluijs</surname><given-names>FA</given-names></name><name><surname>Schoemaker</surname><given-names>RC</given-names></name><etal></etal></person-group><article-title>Peribulbar corticosteroid injection: vitreal and serum concentrations after dexamethasone disodium phosphate injection</article-title><source>Am J Ophthalmol</source><year>1997</year><volume>123</volume><fpage>358</fpage><lpage>363</lpage><pub-id pub-id-type="pmid">9063245</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cardillo</surname><given-names>JA</given-names></name><name><surname>Melo</surname><given-names>LA</given-names><suffix>Jr</suffix></name><name><surname>Costa</surname><given-names>RA</given-names></name><etal></etal></person-group><article-title>Comparison of Intravitreal versus Posterior Sub-Tenon's Capsule Injection of Triamcinolone Acetonide for Diffuse Diabetic Macular Edema</article-title><source>Ophthalmology</source><year>2005</year><volume>112</volume><fpage>1557</fpage><lpage>1563</lpage><pub-id pub-id-type="pmid">16019075</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonini-Filho</surname><given-names>MA</given-names></name><name><surname>Jorge</surname><given-names>R</given-names></name><name><surname>Barbosa</surname><given-names>JC</given-names></name><etal></etal></person-group><article-title>Intravitreal Injection Versus Sub-Tenon's Infusion of Triamcinolone Acetonide for Refractory Diabetic Macular Edema: A Randomized Clinical Trial</article-title><source>Invest Ophthalmol Vis Sci</source><year>2005</year><volume>46</volume><fpage>3845</fpage><lpage>3849</lpage><pub-id pub-id-type="pmid">16186372</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Fig. 1</label><caption><p>Visual acuity in the intravitreal and posterior sub-tenon injected eyes at baseline and at 1 and 3 months after triamcinolone acetonide injection.</p></caption><graphic xlink:href="kjo-20-205-g001"></graphic></fig><fig id="F2" position="float"><label>Fig. 2</label><caption><p>Central macular thickness in the intravitreal and posterior subtenon injected eyes at baseline and at 1 and 3 months after triamcinolone acetonide injection.</p></caption><graphic xlink:href="kjo-20-205-g002"></graphic></fig><fig id="F3" position="float"><label>Fig. 3</label><caption><p>Changes in the OCT images of representative patient in the intravitreal and posterior subtenon injection groups. In an eye that underwent intravitreal injection, the marked macular edema (A) decreased substantially and the eye showed virtually normal macular configuration at 3 months (B) after injection. In an eye that underwent posterior subtenon injection, the macular edema (C) also decreased substantially with time, and the eye showed virtually normal macular configuration at 3 months (D) after injection.</p></caption><graphic xlink:href="kjo-20-205-g003"></graphic></fig><fig id="F4" position="float"><label>Fig. 4</label><caption><p>Intraocular pressure in the intravitreal and posterior subtenon injected eyes at baseline and at 1 and 3 months after triamcinolone acetonide injection.</p></caption><graphic xlink:href="kjo-20-205-g004"></graphic></fig><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Patient Characteristics</p></caption><graphic xlink:href="kjo-20-205-i001"></graphic><table-wrap-foot><fn><p><sup>*</sup>IVTA: intravitreal triamcinolone injection group, <sup>†</sup>PSBTA: posterior subtenon triamcinolone injection group.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Visual Acuity (LogMAR)</p></caption><graphic xlink:href="kjo-20-205-i002"></graphic><table-wrap-foot><fn><p><sup>*</sup><sup>†</sup>PSBTA: posterior subtenon triamcinolone injection group.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Central Macular Thickness (µm)</p></caption><graphic xlink:href="kjo-20-205-i003"></graphic><table-wrap-foot><fn><p><sup>*</sup>IVTA: intravitreal triamcinolone injection group, <sup>†</sup>PSBTA: posterior subtenon triamcinolone injection group.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T4" position="float"><label>Table 4</label><caption><p>Intraocular Pressure (mmHg)</p></caption><graphic xlink:href="kjo-20-205-i004"></graphic><table-wrap-foot><fn><p><sup>*</sup>IVTA: intravitreal triamcinolone injection group, <sup>†</sup>PSBTA: posterior subtenon triamcinolone injection group.</p></fn></table-wrap-foot></table-wrap></floats-group></article>